Proof of Concept of the Aiinane Preoperative Risk Assessment Tool.
Launched by ANCOR SERRANO · Jun 6, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new tool called the Aiinane Preoperative Risk Assessment Tool, designed to help doctors evaluate the risks of patients who are scheduled for breast cancer surgery. The goal is to improve the way patients are assessed before surgery, reducing the chances of last-minute cancellations and ensuring that high-risk patients receive the care they need. The tool uses advanced technology to analyze various health factors, helping to identify patients who are low-risk and those who may need extra attention.
To participate in the trial, individuals must be adults (18 years or older) who are scheduled for surgery to treat breast cancer and are willing to undergo a pre-anesthetic evaluation. It’s important that participants can understand the study and provide written consent. Those who are unable to participate due to other health issues, are scheduled for surgery within a week of enrollment, or are pregnant will not be included. Throughout the study, participants can expect a thorough evaluation to help ensure their safety and prepare them for surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (age ≥18 years) of both sexes. Although breast neoplasia is a pathology with high prevalence in the female biological gender, we do not rule out recruiting patients of male biological gender.
- • Who have been indicated for breast surgery to resolve breast cancer pathology.
- • Who will undergo a pre-anesthetic evaluation during the inclusion period..
- • Subjects must understand the nature of the study procedures and provide written informed consent prior to any study-related procedures.
- Exclusion Criteria:
- • Surgery scheduled for \<7 days from enrollment
- • Inability to participate in the study, in the opinion of the investigator, due to, for example, severe brain damage, language barrier, dementia, or other clinically significant or unstable conditions.
- • Subject's participation in any other clinical study.
- • Subjects dependent (as employee or relative) of the promoter or researcher.
- • Subjects placed in an institution by virtue of an order issued by either judicial or administrative authorities.
- • Limited legal capacity or incapacity.
- • Pregnancy.
About Ancor Serrano
Ancor Serrano is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on precision medicine, Ancor Serrano collaborates with healthcare professionals, regulatory bodies, and research institutions to conduct rigorous clinical studies that adhere to the highest ethical and scientific standards. The organization prides itself on fostering a patient-centric approach, ensuring that the needs and safety of participants are prioritized throughout the research process. Through its commitment to transparency and excellence, Ancor Serrano aims to contribute significantly to the development of groundbreaking treatments across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hospitalet De Llobregat, Barcelona, Spain
Patients applied
Trial Officials
Ancor Serrano Afonso, MD, PhD
Principal Investigator
Bellvitge University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported